These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Sipuleucel-T (APC8015) for prostate cancer. So-Rosillo R; Small EJ Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451 [TBL] [Abstract][Full Text] [Related]
9. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Cheever MA; Higano CS Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival. Peskin SR Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617 [TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
12. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T for the treatment of advanced prostate cancer. Frohlich MW Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047 [TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
15. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Nabhan C N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391 [No Abstract] [Full Text] [Related]
16. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Wei XX; Fong L; Small EJ Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Garcia JA; Dreicer R Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467 [TBL] [Abstract][Full Text] [Related]
19. Continuous improvement versus innovation: the case for sipuleucel-T. Tombal B Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024 [No Abstract] [Full Text] [Related]
20. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]